Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$35.47

-0.03 (-0.08%)

09:43
12/30/17
12/30
09:43
12/30/17
09:43

'Good time' to buy GlaxoSmithKline stock, Barron's says

GalxoSmithKline's earnings estimates have been sliding and shares have tumbled since the summer, but now looks like a good time to buy the stock, Jack Hough writes in this week's edition of Barron's. While GlaxoSmithKline will suffer an earnings hit in 2018 from new generic competition, it should get back on track quickly, he contends. Reference Link

  • 25

    Mar

GSK GlaxoSmithKline
$35.47

-0.03 (-0.08%)

11/24/17
DBAB
11/24/17
NO CHANGE
Target $59
DBAB
Hold
Deutsche cuts Merck target to $59 on competition from AbbVie, GSK
Deutsche Bank analyst Gregg Gilbert lowered his price target for Merck (MRK) to $59 from $62 citing expectations for more competitive pressure on Zepatier and Zostavax. The stock closed Wednesday up 10c to $54.37. Demand trends for Merck's hepatitis C virus drug Zepatier have continued to decline as AbbVie's (ABBV) Mavyret has gained traction, Gilbert told investors in a research note. The analyst also assumes "significant pressure" on Merck's shingles vaccine Zostavax from the near-term competitive launch of GlaxoSmithKline's (GSK) Shingrix. Gilbert views Merck's risk/reward as fairly balanced and he keeps a Neutral rating on the shares.
11/27/17
UBSW
11/27/17
UPGRADE
UBSW
Buy
GlaxoSmithKline upgraded to Buy from Neutral at UBS
UBS analyst Michael Leuchten upgraded GlaxoSmithKline to Buy with an unchanged price target of 1,550p. Concerns of continuing earnings decline and the dividend sustainability are now overdone, Leuchten tells investors in a research note. The analyst believes the dividend looks secure and views the 6% forecast yield as "handsome."
11/27/17
11/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lowe's (LOW) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch saying he views Lowe's shares as more attractive following the third quarter beat. 2. T-Mobile (TMUS) upgraded to Buy from Neutral at MoffettNathanson. 3. GlaxoSmithKline (GSK) upgraded to Buy from Neutral at UBS with analyst Michael Leuchten saying concerns of continuing earnings decline and the dividend sustainability are now overdone. 4. Ciena (CIEN) upgraded to Buy from Neutral at BofA/Merrill with analyst Tal Liani saying shares are at the low end of the historical range and the earnings growth profile is attractive. 5. Constellium (CSTM) upgraded to Outperform from Market Perform at Cowen with analyst Novid Russell saying the company's rapid deleveraging has allowed investors to focus on its significant growth projects, attractive end markets, and valuation discount relative to peers. Russell raised his price target to $13 from $11 on Constellium shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/17
ARGS
11/30/17
NO CHANGE
Target $40
ARGS
Buy
GlaxoSmithKline price target lowered to $40 from $50 at Argus
Argus analyst John Eade lowered his price target on GlaxoSmithKline to $40 but kept his Buy rating, saying that the 10% decline in stock price over the past quarter presents a buying opportunity. Eade attributes the decline to the company lagging its peers in moving beyond the patent cliff as well as pricing pressure and generic threats to its respiratory blockbuster Advair/Seretide. However, the analyst says the new CEO should be able to accelerate the efforts to leverage the company's strengths, which include consumer products, vaccines and anti-infectives.

TODAY'S FREE FLY STORIES

NBL

Noble Energy

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Recommendations
Noble Energy analyst commentary  »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

JNJ

Johnson & Johnson

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Hot Stocks
Johnson & Johnson sees apalutamide approval in 2018 »

Johnson & Johnson CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

ABEO

Abeona Therapeutics

$14.85

0.25 (1.71%)

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Initiation
Abeona Therapeutics initiated  »

Abeona Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

EOG

EOG Resources

09:15
01/23/18
01/23
09:15
01/23/18
09:15
Recommendations
EOG Resources analyst commentary  »

EOG Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FANG

Diamondback Energy

$132.21

4.64 (3.64%)

09:13
01/23/18
01/23
09:13
01/23/18
09:13
Recommendations
Diamondback Energy analyst commentary  »

Diamondback Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

09:13
01/23/18
01/23
09:13
01/23/18
09:13
Hot Stocks
Twitter drops as COO Anthony Noto resigns to become SoFi CEO »

Shares of Twitter (TWTR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

AMRN

Amarin

$4.04

0.07 (1.76%)

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Recommendations
Amarin analyst commentary  »

Amarin shares have room…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Recommendations
Devon Energy analyst commentary  »

Devon Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TWTR

Twitter

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Technical Analysis
Technical Take: Twitter drops on departure of COO Anthony Noto »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

CLR

Continental Resources

09:11
01/23/18
01/23
09:11
01/23/18
09:11
Recommendations
Continental Resources analyst commentary  »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:10
01/23/18
01/23
09:10
01/23/18
09:10
Recommendations
Halliburton analyst commentary  »

Halliburton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXO

Concho Resources

$160.41

4.22 (2.70%)

09:10
01/23/18
01/23
09:10
01/23/18
09:10
Recommendations
Concho Resources analyst commentary  »

Concho Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:09
01/23/18
01/23
09:09
01/23/18
09:09
Technical Analysis
Technical Take: Verizon trades higher after results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

ANAB

AnaptysBio

$114.78

-0.135 (-0.12%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Recommendations
AnaptysBio analyst commentary  »

AnaptysBio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEC

Cimarex Energy

$126.80

2.76 (2.23%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Recommendations
Cimarex Energy analyst commentary  »

Cimarex Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    Feb

DGX

Quest Diagnostics

$103.57

0.51 (0.49%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Hot Stocks
Quest Diagnostics to acquire MedXM for undisclosed amount »

Quest Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:07
01/23/18
01/23
09:07
01/23/18
09:07
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon says FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SLB

Schlumberger

$79.79

3.37 (4.41%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$60.72

2.52 (4.33%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Recommendations
Anadarko analyst commentary  »

Anadarko price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon says 5G trials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

TWTR

Twitter

$23.32

-0.34 (-1.44%)

09:05
01/23/18
01/23
09:05
01/23/18
09:05
Hot Stocks
SoFi names former Twitter COO Anthony Noto as CEO »

SoFi announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

HAL

Halliburton

$56.40

3.39 (6.40%)

09:05
01/23/18
01/23
09:05
01/23/18
09:05
Recommendations
Halliburton analyst commentary  »

Halliburton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$91.89

0.82 (0.90%)

09:04
01/23/18
01/23
09:04
01/23/18
09:04
Hot Stocks
Procter & Gamble sees stronger earnings growth in Q4 than Q3 »

Views tax act as a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

WPP

WPP

$95.32

-0.21 (-0.22%)

09:04
01/23/18
01/23
09:04
01/23/18
09:04
Downgrade
WPP rating change  »

WPP downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$63.94

0.23 (0.36%)

, CHTR

Charter

$370.25

4.2 (1.15%)

09:03
01/23/18
01/23
09:03
01/23/18
09:03
Hot Stocks
T-Mobile closes Layer3 TV acquisition, prepares to take on cable, satellite TV »

T-Mobile US (TMUS)…

TMUS

T-Mobile

$63.94

0.23 (0.36%)

CHTR

Charter

$370.25

4.2 (1.15%)

CMCSA

Comcast

$42.89

0.39 (0.92%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 02

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.